Affimed N.V. Reports Strong Q3 2024 Financial Outcomes
Affimed N.V. (Nasdaq: AFMD), a leader in immuno-oncology, recently shared its financial results and outlined significant developments in its clinical pipeline for the recent quarter. The company, recognized for its commitment to leveraging the innate immune system in cancer therapy, reported that its current cash reserves are projected to support operations into late 2025.
Clinical Pipeline Updates
One impressive highlight for Affimed includes the completion of patient enrollment in the AFM24-102 trial, which combines their novel therapy AFM24 with atezolizumab for the treatment of non-small cell lung cancer (NSCLC) with EGFR wild-type. Safety and early clinical efficacy results from this cohort will be revealed in a future conference call.
Noteworthy Clinical Combinations
In addition, the company is gearing up to present updated clinical data surrounding Acimtamig (AFM13) used alongside AlloNK® at the upcoming ASH 2024. Four distinct cohorts are being highlighted during this session, aiming to showcase the potential of this collaboration in treating patients with hard-to-treat cancers.
AFM28 Monotherapy Study
Affimed also continues to provide updates from its AFM28 phase 1 dose-escalation study for relapsed or refractory acute myeloid leukemia (AML). Updated clinical data is expected to be shared during an oral presentation at ASH 2024, shedding light on the safety and effectiveness of AFM28.
Financial Highlights
As of September 30, 2024, Affimed's total cash, cash equivalents, and short-term investments were reported at €24.1 million. This figure indicates a significant drop from the previous year's reported numbers but reflects the company's strategic financial management amid reduced expenses in research and development. The net cash utilized in operations for Q3 2024 amounted to €11.1 million, showcasing a decrease from €18.3 million in the same quarter the previous year.
Revenue Insights
The total revenue for Affimed in Q3 2024 was €0.2 million, down from €2.0 million in the same period last year, primarily due to differences in collaborative agreements. Revenue in the current quarter derives mainly from licensing arrangements, contrasting with last year’s higher collaborations in research.
Continued Investment in R&D
Research and Development expenses for the same quarter were pegged at €10.1 million, significantly lower than in 2023, reflecting Affimed's commitment to refining its clinical focus while balancing cost-effective operations. While general and administrative expenses also declined to €4.3 million, this reflects the company’s focus on efficiency amidst ongoing operational changes.
Looking Ahead at Future Milestones
Going forward, Affimed has significant milestones to anticipate, including updates on efficacy from the LuminICE-203 study and data presentation from the AFM24-102 trial in 2025. With these upcoming events, Affimed aims to solidify its position within the competitive landscape of immuno-oncology.
About Affimed N.V.
Affimed N.V. is firmly rooted in the advancement of immunotherapy, utilizing its proprietary ROCK® platform to design innate cell engagers (ICE®). These innovative therapies enable targeted treatments for various cancers, indicating a promising path forward for patients battling challenging diagnoses. Headquartered in Mannheim, Germany, the company is committed to turning the tide on cancer through extensive research and robust clinical partnerships.
Frequently Asked Questions
What are the main highlights from Affimed's Q3 2024 report?
Affimed reported a cash position of €24.1 million, a reduction in R&D expenses, and updates on their clinical pipeline.
When will data on AFM24 be available?
The objective response rate and safety data from the AFM24 combination therapy will be presented in a future conference call.
What financial results did Affimed report for Q3 2024?
The company reported total revenue of €0.2 million and a net cash used in operations of €11.1 million.
How has Affimed's revenue changed compared to last year?
Revenue decreased from €2.0 million in Q3 2023 to €0.2 million in the recent quarter.
What is Affimed's strategic focus moving forward?
The company aims to optimize its clinical priorities, demonstrate impactful collaborations, and drive efficiencies in its R&D efforts.
